echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New antisense oligonucleotide therapy has come to effectively inhibit progeria protein to alleviate disease

    New antisense oligonucleotide therapy has come to effectively inhibit progeria protein to alleviate disease

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hutchinson-Gilford Progeria Syndrome (HGPS) is a disease caused by a single nucleotide mutation in the Lamin A gene (LMNA), which is characterized by accelerated aging, defects in the cardiovascular system, and premature death.


    At present, the only treatment option for HGPS is the recently approved lonafarnib, but the drug has treatment limitations such as side effects.


    The most common pathogenic mutation in the LMNA gene is C1824T, which leads to abnormal pre-mRNA splicing, leading to the production of progerin protein, which destroys normal cell nuclear structure and function, and ultimately causes disease.


    In one study, researchers used antisense phosphorodiamidate oligomers (PMO) to prevent RNA splicing: these synthetic nucleotide analogs can prevent the translation of the target sequence and prevent the spliceosome from interacting with the mRNA.


    In another study, the researchers designed and screened 198 ASOs with different target sequences, lengths and chemical properties for fibroblasts derived from patients.


    Two studies have shown that ASO can be delivered to key organs affected by HGPS, thereby reducing the expression of progerin protein and extending the life of mice.


    Reference materials:

    [1] Erdos, MR, Cabral, WA, Tavarez, UL et al.


    [2] Puttaraju, M.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.